Doxycycline to Upgrade Organ Response in Light Chain (AL) Amyloidosis (DUAL) Trial: A Phase II Open Label Study of Oral Doxycycline Administered as an Adjunct to Plasma Cell Directed Therapy in Light Chain (AL) Amyloidosis
Phase: PHASE2
Conditions: Primary Systemic Amyloidosis
Sponsor: Medical College of Wisconsin

Version Date 08-19-16 
1 
 
 
A Phase II open label study of Oral Doxycycline 
administered as an adjunct to plasma cell directed 
therapy in light chain (AL) amyloidosis. 
 
 
 
Principal Investigator: 
Anita D’Souza, MD 
 
Assistant Professor of Medicine   
 
Division of Hematology and Oncology 
 
Froedtert Hospital and the Medical College of Wisconsin 
 
9200 W. Wisconsin Ave. 
 
Milwaukee, WI 53226 
 
Co-Investigators: 
Parameswaran Hari, MD 
 
Carlos Arce-Lara, MD 
 
 
 
Statistician: 
Mei-Jie Zhang, PhD 
 
Division of Biostatistics 
 
Medical College of Wisconsin 
 
8701 Watertown Plank Road 
 
Milwaukee, WI 53226 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

Version Date 08-19-16 
2 
 
Study Coordinators 
Paulette Jacobs, BS, MS, CCRP 
Clinical Research Manager 
Cancer Center Clinical Trials Office 
Froedtert Hospital and the Medical College of Wisconsin 
9200 W. Wisconsin Ave. 
Milwaukee, WI 53226 
Phone: 414-805-4594 
Fax: 414-805-0596 
Email: pjacobs@mcw.edu  
 
Kirsten Jacobson, RN, MS  
Clinical Research Nurse 
Cancer Center Clinical Trials Office  
Froedtert Hospital and the Medical College of Wisconsin 
9200 W. Wisconsin Ave. 
Milwaukee, WI   53226 
Phone: (414) 805-0769  
Fax: (414) 805-8840 
 
 
Pharmacists 
Kristin Busse, Pharm D. 
Investigational Drug Pharmacy 
Froedtert Hospital  
9200 W Wisconsin Ave 
Milwaukee, WI 53226 
 
 
Abbreviations: 
AL amyloidosis- immunoglobulin light chain amyloidosis 
H&P- history & physical 
CBC- complete blood count 
β-HCG- Beta human chorionic gonadotropin 
KPS- Karnofsky Performance Status 
LVEF- left ventricular ejection fraction 
NT-proBNP- N-terminal pro-Brain Natriuretic Peptide 
BID- twice daily 
CyBorD- Cyclophosphamide/Bortezomib/Dexamethasone 
CyBorP- Cyclophosphamide/Bortezomib/Prednisone 
Mel/Dex- Melphalan/Dexamethasone 
 
 
 

Version Date 08-19-16 
3 
 
Synopsis 
A Phase II open label study of Oral Doxycycline 
administered as an adjunct to plasma cell directed 
therapy in light chain (AL) amyloidosis. 
 
PRIMARY OBJECTIVES: 
1. Determine the efficacy of adjunctive doxycycline in addition to specific anti plasma cell 
therapy in patients with AL amyloidosis in improving amyloid organ response at 1 year.  
2. Assess the safety of doxycycline + anti-plasma cell chemotherapy regimen in AL 
amyloidosis. 
 
SECONDARY OBJECTIVES: 
1. To assess rates of hematologic response. 
2. To assess rates of mortality at 1 month, 6 months and 1 year. 
3. To measure patient reported outcomes at baseline, 3, 6, 9 and 12 months. 
4. To evaluate biomarkers associated with anti-amyloid response. 
 
STUDY DESIGN: 
This is a phase II study of doxycycline for 1 year, used as an adjunct to plasma cell directed 
therapy, to improve amyloid organ response. 
 
PATIENT ELIGIBILITY CRITERIA: 
 
Inclusion Criteria: 
1. Patients with biopsy proven AL amyloidosis. 
2. Patients ≥ 18 years of age are eligible.  
3. Patient must provide informed consent.  
4. All patients must have measurable amyloid organ involvement of a vital organ 
(heart, liver, kidneys). Localized amyloidosis will be eligible as long as the 
amyloid involvement is radiologically measurable. 
5. A negative pregnancy test will be required for all women of child bearing 
potential. Breast feeding is not permitted.  
6. Patients with history of intolerance or allergic reactions with doxycycline will not 
be eligible.  
7. Patients who have previously been taking doxycycline will be eligible as long as 
there is no contraindication to stay on doxycycline 100 mg BID for 1 year in the 
opinion of the treating physician. 
8. Creatinine clearance of >25 ml/min. 

Version Date 08-19-16 
4 
 
Exclusion Criteria: 
1.  Patients with severe malabsorption syndrome precluding absorption of oral agents 
will be excluded.  
2.  Known intolerance or allergic reactions with doxycycline. 
3.  Previous chemotherapy for AL amyloidosis. 
 
 
Patient Treatment Plan 
 
 
 
 
Step 1
•Registration
•Baseline evaluations per table of events for systemic or localized 
amyloidosis
Step 2
•Start doxycycline 100 mg BID orally
•Acceptable anti-amyloid regimens include CyBorD, Mel/Dex, CyBorP, high 
dose melphalan
•If no systemic therapy is planned for AL amyloidosis, patients may still be 
enrolled if they have measurable renal, cardiac, liver or localized 
amyloidosis.
Step 3
•Continue doxycycline until: (1) Day +360 or until patient is off IST, (2) patient 
develops progressive disease necessitating change of treatment, or (3) 
patient develops any grade 3-4 toxicity related to doxycycline.
•Monthly  visits for systemic amyloid ; Every 3 month visits for localized 
amyloid
•Months 6, 12- correlative serum specimens

Version Date 08-19-16 
5 
 
TABLE OF CONTENTS_ 
1. INTRODUCTION: .................................................................................................................................................. 7 
1.1 Amyloidosis: ....................................................................................................................................................... 7 
1.2 Tetracyclines: ...................................................................................................................................................... 7 
1.3 Doxycycline effects in Amyloidosis: .................................................................................................................. 8 
1.4 Clinical experience with Doxycycline: ............................................................................................................... 8 
1.5 Clinical data of Doxycycline in Amyloidosis: .................................................................................................... 9 
1.6 Limitations of current AL amyloidosis therapy: ................................................................................................. 9 
1.7 Study Rationale: ................................................................................................................................................ 11 
2.  OBJECTIVES ....................................................................................................................................................... 11 
2.1 Primary Objectives: .......................................................................................................................................... 11 
2.2 Secondary Objectives: ...................................................................................................................................... 11 
3. PATIENT ELIGIBILITY: .................................................................................................................................... 11 
3.1 Inclusion Criteria: ............................................................................................................................................. 11 
3.2 Exclusion Criteria: ............................................................................................................................................ 12 
4.  REGISTRATION PROCEDURE: ...................................................................................................................... 12 
4.1 Registration ....................................................................................................................................................... 12 
5. TREATMENT PLAN: .......................................................................................................................................... 12 
5.1 Administration schedule to Patients .................................................................................................................. 12 
5.2 Dose modification ............................................................................................................................................. 14 
5.3 Duration of therapy ........................................................................................................................................... 14 
5.4 Data Safety Monitoring Plan ............................................................................................................................ 14 
6.  MEASUREMENT OF EFFECT: ........................................................................................................................ 15 
6.1 Visit Schedule: .................................................................................................................................................. 15 
6.2 Amyloid Response Assessment: ....................................................................................................................... 15 
7.  STUDY PARAMETERS (STUDY CALENDAR): ............................................................................................ 16 
7.1 Patient Study Calendar:..................................................................................................................................... 16 
8. 
DRUG FORMULATION AND PROCUREMENT ...................................................................................... 20 
8.1 Doxycycline monohydrate ................................................................................................................................ 20 
8.1.1 Drug description ............................................................................................................................................ 20 
8.1.2 Pharmacodynamics ........................................................................................................................................ 21 
8.1.3 Pharmacokinetics .......................................................................................................................................... 21 
8.1.4 Contraindications .......................................................................................................................................... 21 
8.1.5 Drug Interactions ........................................................................................................................................... 22 
8.1.6 Adverse Events:............................................................................................................................................. 22 
8.2 How supplied and Storage/Handling ................................................................................................................ 23 
8.3 Methods of procurement ................................................................................................................................... 23 
9. 
STATISTICAL CONSIDERATIONS ............................................................................................................ 24 
10. ADVERSE EVENT REPORTING REQUIREMENTS ................................................................................... 25 
10.1  Definitions ..................................................................................................................................................... 25 
11. PATIENT CONSENT AND PEER REVIEW STATEMENT ......................................................................... 29 
11.1 Subject Information and Informed Consent .................................................................................................... 29 
12.  PATIENT REPORTED OUTCOMES ASSESSMENT .................................................................................. 30 
13. CORRELATIVE SPECIMENS ......................................................................................................................... 30 

Version Date 08-19-16 
6 
 
14.  REFERENCES ................................................................................................................................................... 31 
15. 
APPENDIX A ................................................................................................................................................... 34 
16. 
APPENDIX B ................................................................................................................................................... 36 
 
 
 
 
 

Version Date 08-19-16 
7 
 
1. INTRODUCTION:   
1.1 Amyloidosis: 
The amyloidoses are a diverse group of protein misfolding diseases wherein proteins 
aggregate and form fibrillar deposits (amyloid) in tissues.1 Examples of amyloid diseases 
include Alzheimer’s disease, hereditary transthyretrin-associated familial amyloid 
polyneuropathy, dialysis related amyloidosis, AA amyloidosis with chronic systemic 
inflammatory states and immunoglobulin-derived AL amyloidosis. Human amyloid-
associated illnesses pose a therapeutic challenge since amyloid is a long-lived protein and 
there are no approved drugs demonstrated to disrupt pre-formed amyloid.  
AL amyloidosis is a malignant plasma cell disease characterized by the formation of amyloid 
from immunoglobulin light chains produced by clonal plasma cells.1 The amyloid deposits 
into vital organs such as the heart, liver, kidney, and nerves resulting in inexorable systemic 
decline in function and culminating in death. Of the 27 known proteins resulting in 
amyloidosis in humans, AL amyloidosis is the most common and the most rapidly fatal with 
a median survival of 6 months in advanced disease.2 The drugs most frequently used to treat 
AL amyloidosis eradicate cells that produce AL amyloid protein but have no effect on pre-
formed amyloid (see below). 
1.2 Tetracyclines:  
The tetracyclines are a well-established family of broad-spectrum antimicrobials first isolated 
from Streptomyces aureofaciens in 1947 from soil screening.3 Semisynthetic tetracyclines 
were developed for antibacterial use, of which doxycycline is one. Their antibiotic effect is 
primarily mediated by binding to the bacterial ribosome and inhibiting protein synthesis.  
Separate from their anti-microbial effect, tetracyclines, including doxycycline, possess the 
ability to inhibit members of the matrix metalloproteinase (MMP) family of endopeptidases. 
The MMPs are zinc-dependent proteases involved in a gamut of physiological and 
pathophysiological processes such as embryogenesis, tissue remodeling, inflammation and 
tumor invasion.4 It is hypothesized that overproduction of MMPs can result in AL renal and 
cardiac damage.5,6 High levels of MMPs appear to correlate with diastolic dysfunction and 
clinical manifestations of AL cardiomyopathy.6 Doxycycline-induced inhibition of MMPs 
appears to be beneficial in conditions associated with pathologic MMP-mediated proteolysis 
of the extracellular matrix, including cardiac remodeling, periodontitis, arthritis and cancer.7-9 

Version Date 08-19-16 
8 
 
Owing to its lipophilicity, doxycycline also concentrates in organs at sites of injury including 
gums in gingivitis, brain in meningitis and the myocardium in infarcts.10  
1.3 Doxycycline effects in Amyloidosis: 
The first report of the anti-amyloidogenic activity of doxycycline was suggested in a study of 
Alzheimer’s disease.11 Forloni, et al, showed that co-incubation of tetracyclines with β 1-42 
synthetic peptide, which is highly represented in Alzheimer amyloid deposits, resulted in a) 
marked reduction of amyloid fibril formation, b) inhibition of amyloid aggregation and c) de-
fibrillogenic effect against pre-formed amyloid fibrils.11 Cardoso, et al, tested various 
tetracyclines and showed doxycycline to be the most effective of the family in disrupting 
transthyretrin amyloid fibrils after incubation.12 This group also showed that the anti-amyloid 
effect is independent of the amyloid precursor protein.13 Doxycycline also disrupted amyloid 
in animal models, including a familial amyloid polyneuropathy transgenic mouse model.14 
Further studies showed that tetracyclines also produced de-structuration of β2-microglobulin 
in dialysis related amyloidosis15 In AL amyloidosis, Ward, et al, showed that doxycycline 
can inhibit amyloid fibril aggregation and can destroy preformed amyloid in vitro and in a 
transgenic murine AL model.16 
1.4 Clinical experience with Doxycycline: 
Doxycycline is well-tolerated and safe, and is widely used in clinical practice for 
antibacterial prophylaxis, community acquired pneumonia and chronic obstructive 
pulmonary disease. It is also efficacious in unusual infections such as Lyme disease, cholera, 
syphilis, plague and malaria.10 The side-effect profile of doxycycline is well-studied. 
Prolonged doxycycline administration at doses of 100 -200 mg daily for 6-24 months is well 
tolerated.17-19 Commonly described adverse events with doxycycline use are cutaneous 
photosensitivity and self-limiting non-specific gastrointestinal symptoms.18,19 Within our 
oncology practice, doxycycline is commonly used in patients with solid tumors and 
hematologic malignancies for anti-microbial prophylaxis in the setting of chemotherapy-
induced neutropenia, particularly in patients with penicillin allergies with good tolerance.17,20 
 
 

Version Date 08-19-16 
9 
 
1.5 Clinical data of Doxycycline in Amyloidosis: 
There are limited but positive data suggesting an anti-amyloid efficacy of doxycycline in 
humans. Montagna, et al, treated 3 patients with severe painful arthropathy related to β2-
microglobulin dialysis related amyloidosis with resolution of arthropathy in all three 
patients.21 Kumar, et al, reviewed a large cohort of AL patients who underwent stem cell 
transplantation for therapy, and received a year of doxycycline treatment for anti-bacterial 
prophylaxis. They found that among patients who had a hematologic response to stem cell 
transplantation, those patients on doxycycline prophylaxis had a higher survival rate than 
those on penicillin G prophylaxis.20 This study also suggested the tolerability and safety of 
doxycycline administration in AL amyloidosis patients even in the critical post-transplant 
setting.20 Doxycycline is currently being studied in patients with familial amyloid 
polyneuropathy. 
1.6 Limitations of current AL amyloidosis therapy: 
The current paradigm of AL amyloid treatment is focused upon eradicating the underlying 
malignant plasma cell clone with cytotoxic agents. This produces a hematologic response by 
clearing circulating immunoglobulin light chains which would have eventually been 
deposited into amyloid. Treatments range from high dose therapy with autologous stem cell 
transplantation in eligible patients, or anti-myeloma chemotherapy regimens such as 
melphalan/dexamethasone.22 Newer anti-myeloma agents such as thalidomide,23,24 
lenalidomide,25-28 pomalidomide,29 and bortezomib30,31 have excellent anti-plasma cell 
efficacy in amyloidosis but are also associated with organ and tissue toxicity making their 
use in clinical practice challenging, particularly in advanced AL disease.32  Treatment of AL 
amyloidosis thus remains a frustrating journey for patients and their treating physicians, 
where clinically tenuous and frail patients with compromised vital organ function are treated 
with cytotoxic chemotherapy that often rapidly clears light chains from serum (i.e. 
hematologic response) but does not rapidly improve organ function.  Many of these patients 
succumb to organ failure despite hematologic response.  Indeed, in many patients with 
advanced stage cardiac amyloidosis, use of newer anti-myeloma drugs such as lenalidomide 
and bortezomib causes an initial worsening in cardiac biomarkers and even death.25,30,32 
Patients with advanced stage amyloidosis have a 40% risk of mortality in the first year 
following diagnosis, a number that has not changed since the 1970s (Figure 1) 2 despite the 

Version Date 08-19-16 
10 
 
availability of more effective anti-myeloma chemotherapy that have clearly improved 
myeloma outcomes during the same time frame.33  
 
 
Figure 1. Overall survival of AL amyloidosis divided over three time periods. This figure 
shows that in the first year following diagnosis, 40% of patients die with no change in the 
three time periods.2 
As outlined above, there is a clear need to identify treatments that do more than eradicate 
the malignant clone (the primary objective of anti-myeloma therapies) to improve the 
high early mortality that occurs even while on “effective” chemotherapy. Thus, 
consideration of therapies that complement current cytotoxic anti-amyloid treatment by 
hastening organ response is required. The compelling preclinical data of doxycycline’s 
potential to benefit amyloidosis support prospective investigation of testing the use of 
doxycycline for AL amyloidosis treatment. The current study aims to generate key safety 
and efficacy data of doxycycline administration to AL amyloidosis patients. Our patients 
will potentially benefit from a novel mechanism of anti-amyloid effect in conjunction 
with anti-plasma cell chemotherapy with minimal additional risks and side-effects and, 
perhaps, even an added benefit of simultaneous anti-microbial activity.  
 

Version Date 08-19-16 
11 
 
1.7 Study Rationale: 
Organ response to anti-plasma cell therapy in AL amyloidosis lags behind hematologic 
response as chemotherapy has no effect on pre-formed amyloid.32 Doxycycline has 
pleiotropic, de-fibrillogenic and inhibitory effects on amyloid fibrils shown to be 
beneficial in in vitro, in murine  models and other preclinical studies. We will 
prospectively evaluate the safety and efficacy of  doxycycline in AL amyloidosis 
patients. 
2.  OBJECTIVES 
2.1 Primary Objectives: 
1. Determine the efficacy of adjunctive doxycycline in addition to specific anti plasma cell 
therapy in patients with AL amyloidosis in improving amyloid organ response at 1 year.  
2. Assess the safety of doxycycline + anti-plasma cell chemotherapy regimen in AL 
amyloidosis. 
2.2 Secondary Objectives: 
1. To assess rates of hematologic response. 
2. To assess rates of amyloid organ response at months 6 and 12. 
3. To assess rates of mortality at 1 month, 6 months and 1 year. 
4. To measure patient reported outcomes at baseline, 3, 6, 9 and 12 months. 
5. To evaluate biomarkers associated with anti-amyloid response. 
3. PATIENT ELIGIBILITY: 
3.1 Inclusion Criteria: 
1. Patients with biopsy proven AL amyloidosis. 
2. Patients ≥18 years of age are eligible.  
3. Patient must provide informed consent.  
4. All patients must have measurable amyloid organ involvement of a vital organ (heart, 
liver, kidneys). Localized amyloidosis will be eligible as long as the amyloid 
involvement is radiologically measurable. 
5. A negative pregnancy test will be required for all women of child bearing potential. 
Breast feeding is not permitted.  
6. Patients who have previously been taking doxycyline will be eligible as long as there is 
no contraindication to stay on doxycycline 100 mg BID for 1 year in the opinion of the 
treating physician. 
7. Creatinine clearance of >25 ml/min. 

Version Date 08-19-16 
12 
 
 
3.2 Exclusion Criteria: 
1.  Patients with severe malabsorption syndrome precluding absorption of oral agents will 
be excluded.  
2. Known intolerance or allergic reactions with doxycycline. 
3. Previous chemotherapy for AL amyloidosis. 
4.  REGISTRATION PROCEDURE: 
4.1 Registration  
• 
All source documents that support eligibility including a signed informed 
consent/HIPAA and signed eligibility checklist, should be available review and 
eligibility verification.   
• 
At the point of registration, the research nurse or data manager will register the patient in 
the electronic database, including demographic, consent and on-study information.  The 
patient will be assigned a unique sequence number for the study. 
5. TREATMENT PLAN: 
This is a phase II study of doxycycline as an adjunct to anti-amyloid treatment in patients with 
AL amyloidosis.  
5.1 Administration schedule to Patients  
1. Doxycycline will be administered at dose of 100mg orally twice daily. Baseline blood 
and urine laboratory testing must be completed within 28 days prior to starting 
doxycycline. 
2. Patients who have previously been taking doxycycline will be eligible as long as there 
is no contraindication to take doxycycline (200mg/day) and continue for 1 year in the 
opinion of the treating physician.  
3. Patients undergoing chemotherapy for AL amyloidosis can receive one of following 
regimens: 
a. Melphalan/Dexamethasone (Palladini regimen)22 
Oral Melphalan 0.22 mg/kg + Dexamethasone 40 mg , Days 1-4, every 28 
days 
b. Cyclophosphamide/Bortezomib/Dexamethasone.34  

Version Date 08-19-16 
13 
 
Cyclophosphamide 300 mg/m2 + Bortezomib 1.3 mg/m2 + Dexamethasone 40 
mg, days 1, 8, 15 every 28 days. Any combinations of these medications will 
be allowed based on treating clinician’s judgement. 
c. High dose Melphalan/Stem Cell rescue.35 
IV Melphalan 140-200 mg/m2 followed by autologous stem cell infusion 
d. Other chemotherapy regimens will be permitted after consultation with study 
PI. Dose modifications in treatments will be allowed per opinion of the 
treating physicians. 
4. Antibiotic prophylaxis in patients undergoing high dose melphalan will be given 
according to institutional guidelines. Routine antibacterial prophylaxis will be 
substituted with doxycycline. If clinically indicated, additional antibacterial coverage 
will be provided depending on physician judgment. 
5. Temporary interruption (≤10-14days) of doxycycline is permitted in patients unable 
to tolerate oral intake secondary to severe nausea, vomiting, mucositis etc. In case 
doxycycline therapy is interrupted, the time interval should be recorded. 
6. Patients with severe macroglossia from amyloid involvement will have the option of 
using doxycycline oral suspension. 
7. Toxicity will be evaluated according to CTCAE v4.0. 
8. Hematologic response following treatment will be recorded at monthly intervals until 
chemotherapy is stopped or no longer indicated. 
9. Organ response will be recorded at 6 and 12 months using RECIST criteria.36 
10. Overall survival will be measured at 1 month, 6 months, 12 months, and yearly until 
five years. 
11. If chemotherapy is switched due to inadequate hematologic response, continued 
doxycycline use will be permitted.  
12. Patients on warfarin will be monitored as doxycycline may enhance anticoagulant 
effect of warfarin. 
13. Patients on antacids containing aluminum, calcium or magnesium and iron-containing 
preparations can impair absorption of doxycycline. Doxycycline administration will 
be 2 hours before or after any of these medications. Since dairy products also contain 

Version Date 08-19-16 
14 
 
calcium, patients will be counselled to avoid dairy products 2 hours before and after 
doxycycline ingestion.  
5.2 Dose modification 
1. Patients experiencing a grade 3-4 hematological or non-hematological toxicity (as 
specified in CTCAE v4.0) thought to be related to doxycycline will be removed from 
the study permanently. The following dose modifications for doxycycline will be 
permitted : Dose lowering down to 50 mg BID may be permitted if patient cannot 
tolerate 100 mg BID due to side effects. 
5.3 Duration of therapy 
Doxycycline will be continued until one of the following criteria is met: 
-Patient has completed 1 year of doxycycline therapy 
-Patient develops any grade 3-4 toxicity related to doxycycline use. 
Patients experiencing an amyloid hematologic relapse can continue doxycycline at the 
discretion of treating physician as long as there is no organ worsening.  
Patients who discontinue prior to 1 year of doxycycline therapy should have an End of 
Treatment visit.  
5.4 Data Safety Monitoring Plan 
This study will be reviewed by the Medical College of Wisconsin Cancer Center Data 
Safety Monitoring Committee (MCW CC DSMC). A summary of the MCW CC DSMC 
activities are as follows:  
• 
Review the clinical trial for data integrity and safety  
• 
Review all unexpected grade 3, and all grade 4, and 5 adverse events, as 
well as any others requiring expedited reporting as defined in this 
protocol. Review all DSM reports  
• 
Submit a summary of any recommendations related to study conduct  
• 
Terminate the study if deemed unsafe for patients  
A copy of the MCW CC Data and Safety Monitoring Plan and membership roster will be 
maintained in the study research file and updated as membership changes. The committee 

Version Date 08-19-16 
15 
 
will review reports from the study PI twice annually (or more frequently if needed) and 
provide recommendations on trial continuation, suspension or termination as necessary. 
 
Any available DSMC letters will be submitted to the IRB of record as required. 
6.  MEASUREMENT OF EFFECT: 
6.1 Visit Schedule: 
The schedule for the study is shown in the table below. 
Study Visit  
Target Day  
Baseline  
 Day -1 to -42 
Month 1 
Day 0  
Month 2 
Day 30 ± 5 
Month 3 
Day 60 ± 7  
Month 4 
Day 90 ± 10  
Month 5 
Day 120 ± 10  
Month 6 
Day 150 ± 10  
Month 7 
Day 180 ± 15  
Month 8 
Day 210 ± 15  
Month 9 
Day 240 ± 15  
Month 10 
Day 270 ± 21  
Month 11 
Day 300 ± 21  
Month 12 
Day 330 ± 28  
End of study treatment 
Day 360 ± 30 
 
*After 12months, patients will be followed at least yearly for survival, amyloid 
relapse and cause of death for 5 years post treatment. 
 
6.2 Amyloid Response Assessment: 
Amyloid hematologic response assessment will be undertaken at monthly intervals using 
serologic studies with a serum protein electrophoresis, immunofixation electrophoresis and 
free light chain analysis. Monthly troponin-T, NT-pro BNP, alkaline phosphatase, creatinine 
will also be obtained per clinical physician’s judgment. 
Formal organ assessments will be undertaken at months 6 and 12. For patients with cardiac 
involvement, an echocardiogram will be repeated in addition to troponin-T and NT-pro 
BNP. For patients with liver involvement, an abdominal ultrasound and alkaline 
phosphatase will be done. For patients with renal involvement, a 24 hour urinary protein 
with urine protein electrophoresis and immunofixation electrophoresis will be checked. 

Version Date 08-19-16 
16 
 
For patients with localized amyloidosis, radiologic testing with a CT scan will be conducted.  
 
Hematologic Response Grading37(See Appendix A) 
Complete response (CR) – Negative serum/urine immunofixation with normal FLC ratio 
 
Very Good Partial Response (VGPR)- Difference between involved and uninvolved FLCs 
(dFLC) < 40 mg/L 
 
Partial Response (PR)- dFLC decrease > 50% 
 
No Response (NR)- less then PR. 
 
 
Organ Response Grading32(See Appendix A) 
Heart 
NT-proBNP response >30% and > 300 ng/L decrease in patients with baseline NT-proBNP 
≥650 ng/L (Patients with progressively worsening renal function cannot be scored for NT-
proBNP progression). 
 
Improvement by 2 NYHA classes without an increase in diuretic use or in echocardiographic 
wall thickness. 
 
≥ 2 mm reduction in the interventricular septal thickness by echocardiogram or 
Improvement of ejection fraction by ≥20%. 
 
Liver 
≥50% decrease in an initially elevated alkaline phosphatase level, or 
Decrease in liver size by at least 2 cm by ultrasound. 
 
Kidney 
50% reduction in 24-hour urine protein excretion (at least 0.5 g/day) without worsening of 
creatinine or creatinine clearance by 25% over baseline. 
 
7.  STUDY PARAMETERS (Study Calendar): 
7.1 Patient Study Calendar:  
The table below summarizes the patient clinical assessments over the course of the study.* 

Version Date 08-19-16 
17 
 
Systemic Amyloidosis 
 
Months 
 
 
Baseline^ 
1^ 
2 
3 
4 
5 
6 
7 
8 
9 
10 
11 
12 
End of Treatment (within 30 
days) 
Inclusion & Exclusion criteria 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Informed consent  
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
H & PE1 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Vital signs2 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
ECOG performance status 
X 
 
 
X 
 
 
X 
 
 
X 
 
 
X 
X 
NYHA class 
X 
 
 
 
 
 
X8 
 
 
 
 
 
X8  
X8 
Complete Blood Count with differential 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Serum chemistries panel3 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Amyloid subtype# 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Beta2 microglobulin 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Myeloma screening panel4 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
Bone marrow aspirate/biopsy 
X7 
 
 
 
 
 
 
 
 
 
 
 
 
 
Β-HCG serum pregnancy test 5 
X 
 
 
 
 
 
 
 
 
 
 
 
 
 
Bone survey11 
X7 
 
 
 
 
 
 
 
 
 
 
 
 
 
2D echocardiogram (IVS + LVEF) 
X 
 
 
 
 
 
X8 
 
 
 
 
 
 
X8† 
Troponin-T, NT-proBNP 
X 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X8 
X8† 
Abdominal Imaging 
X7 
 
 
 
 
 
X9 
 
 
 
 
 
 
X9† 
24 hour urinary protein with 
UPEP/immunofixation 
X10 
 
 
X10 
 
 
X10 
 
 
X10 
 
 
 
X10 † 
Toxicity assessment 
 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
 
Research specimens 6 
X 
 
 
 
 
 
 
X 
 
 
 
 
 
X† 
Patient questionnaire (Appendix B) 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 
X 

Version Date 08-19-16 
18 
 
Notes  
H & PE= history and physical examination 
ECOG- Eastern Co-operative Oncology Group performance score 
NYHA- New York Heart Association Class 
2D echocardiogram- Two-dimensional transthoracic echocardiogram 
IVS- interventricular septal thickness 
LVEF- left ventricular ejection fraction 
^ Baseline and Month 1 can occur within 7 days without the need to repeat the Month 1 testing. 
# If a patient has had amyloid subtyping performed in the past, this need not be repeated again. 
† May be performed anytime during cycle 12 or within 30 days of the last dose of doxycycline 
1History is only required at baseline. 
2Vital signs: blood pressure, pulse rate, respiratory rate and temperature. 
3Serum chemistries panel: electrolytes, BUN, ALT, AST, creatinine, bilirubin, alkaline phosphatase, 
LDH, albumin, uric acid. Electrolytes to include sodium, potassium, chloride, carbon dioxide, and 
calcium. 
4Myeloma screening panel includes serum protein electrophoresis, immunofixation electrophoresis, 
free light chain assay 
5Females of reproductive potential only. 
6Peripheral blood specimens: draw 6 mL in  green top  (heparin containing) tube at indicated time 
points and send to the Tissue Bank at MCW after processing. Samples should be labeled with patient 
study number, date of collection, time point (baseline, 6 months or End of Treatment and MCW/FH 
IRB PRO number. 
7 May be performed within 3 months of baseline 
8Cardiac assessment will be followed only if baseline cardiac involvement 
9Abdominal imaging will be performed only if there is a suspicion of hepatic or splenic involvement 
based on hepatomegaly or splenomegaly on physical examination or labs (increased alkaline 
phosphatase greater than or equal to twice the upper limit of normal) and repeated only if there is 
baseline organ involvement 
10Urinary studies: A urine protein/creatinine ratio which has ~100% concordance to 24 hour urinary 
protein will be allowed to test for baseline renal involvement. Urinary studies will be repeated only if 
baseline renal involvement. The urine test will remain consistent for a given patient, eg. if baseline 
urinary test was 24 hour urinary protein, the follow up tests for that patient will also be 24 hour 
urinary protein. 
11 Not required if ≤10% plasma cells in bone marrow 

Version Date 08-19-16 
19 
 
 
 
Classic localized amyloidosis 
 
 
Baseline^ 
1^ 
4 
7 
10 
End of Treatment (within 30 
days) 
Inclusion & Exclusion criteria 
X 
 
 
 
 
 
Informed consent  
X 
 
 
 
 
 
H & PE1 
X 
X 
X 
X 
X 
X 
Vital signs2 
X 
X 
X 
X 
X 
X 
ECOG performance status 
X 
 
X 
X 
X 
X 
Complete Blood Count with differential 
X 
X 
X 
X 
X 
X 
Serum chemistries panel3 
X 
X 
X 
X 
X 
X 
Amyloid subtype# 
X 
 
 
 
 
 
Beta2 microglobulin 
X8 
 
 
 
 
 
Myeloma screening panel4 
X 
X8 
X8 
X8 
X8 
X8 
Β-HCG serum pregnancy test 5 
X 
 
 
 
 
 
Troponin-T, NT-proBNP 
X8 
 
 
 
 
 
24 hour urinary protein with UPEP/immunofixation 
X8* 
 
 
 
 
 
Bone marrow aspirate/biopsy 
X* 
 
 
 
 
 
2D echocardiogram (IVS + LVEF) 
X* 
 
 
 
 
 
Abdominal Imaging 
X* 
 
 
 
 
 
Radiologic imaging7 
X 
 
 
X 
 
X† 
Toxicity assessment 
 
X 
X 
X 
X 
 
Research specimens 6 
X 
 
 
X 
 
X† 
Patient questionnaire (Appendix B) 
X 
 X 
X 
X   X 
X 
 
Notes 
H & PE= history and physical examination 
ECOG- Eastern Co-operative Oncology Group performance score 
^ Baseline and Month 1 can occur within 7 days without the need to repeat the Month 1 testing. 
† May be performed anytime during cycle 12 or within 30 days of the last dose of doxycycline 
*Bone marrow evaluation, 2D echocardiogram, Abdominal Ultrasound and 24 hour urine protein test 
may be held based on the treating physician’s judgment. 
# If a patient has had amyloid subtyping performed in the past, this need not be repeated again. 
1History is only required at baseline. 

Version Date 08-19-16 
20 
 
2Vital signs: blood pressure, pulse rate, respiratory rate and temperature. 
3Serum chemistries panel: electrolytes, BUN, ALT, AST, creatinine, bilirubin, alkaline phosphatase, 
LDH, albumin, uric acid. Electrolytes to include sodium, potassium, chloride, carbon dioxide, and 
calcium. 
4Myeloma screening panel includes serum protein electrophoresis, immunofixation electrophoresis, 
free light chain assay. 
5Females of reproductive potential only. 
6Peripheral blood specimens: draw 6 mL in green top (heparin containing) tube at indicated time 
points and send to the Tissue Bank at MCW after processing. Samples should be labeled with patient 
study number, date of collection, time point (baseline, 7 months or End of Treatment) and MCW/FH 
IRB PRO number. 
7Radiologic imaging: as clinically indicated  
8 Per MD discretion  
8. Drug Formulation and Procurement 
8.1 Doxycycline monohydrate 
8.1.1 Drug description 
Doxycycline is a synthetic antibacterial drug derived from oxytetracycline and 
available for oral administration. Doxycycline monohydrate has the empirical 
formula of C22H24N2O8.H2O and a molecular weight of 462.46. The chemical 
designation for doxycycline is 4-(Dimethylamino)-1,4,4a,5,5a,6,11,12a-
octahydro-3,5,10,12,12a pentahydroxy-6-methyl-1,11-dioxo-2-
naphthacenecarboxamide monohydrate. It is a light yellow crystalline powder and 
very slightly soluble in water. It has a high degree of lipod solubility and a low 
affinity for calcium binding. It is highly stable in normal human serum. It is 
available in syrup, capsule, oral suspension and tablet formulations. Inert 
ingredients in the tablet formulation are ethylcellulose; hypromellose; magnesium 
stearate; microcrystalline cellulose; propylene glycol; sodium lauryl sulfate; talc; 
titanium dioxide; Yellow 6 Lake. Inert ingredients for the oral suspension 
formulation are: carboxymethylcelluose sodium; Blue 1; methylparaben; 
microcrystalline cellulose; propylparaben; raspberry flavor; Red 28; simethicone 
emulsion; sucrose. 

Version Date 08-19-16 
21 
 
 
 
 8.1.2 Pharmacodynamics 
Tetracyclines are readily absorbed and bound to plasma proteins in varying 
degree. They are concentrated by the liver in the bile, and excreted in the urine 
and feces at high concentrations and in a biologically active form. Doxycycline is 
virtually completely absorbed after oral administration. 
8.1.3 Pharmacokinetics 
Doxycycline is virtually completely absorbed after oral administration. 
Following a 200 mg dose, normal adult volunteers averaged peak serum levels of 
2.6 mcg/ml of doxycycline at 2 hours, decreasing to 1.45 mcg/ml at 24 hours. 
Excretion of doxycycline by the kidney is about 40%/72 hours in individuals with 
normal renal function. This percentage excretion may fall as low as 1-5%/72 
hours in individuals with severe renal insufficiency (creatinine clearance below 10 
ml/min). Studies have shown no significant difference in serum half-life of 
doxycycline (range 18-22 hours) in individuals with normal and severely impaired 
renal function.  
 8.1.4 Contraindications  
Hypersensitivity to any Component of this Medication 
Pregnancy 
Nursing Mothers 
Children under 8 years 
Active Clostridium difficile associated disease 
 

Version Date 08-19-16 
22 
 
 8.1.5 Drug Interactions 
 
Interacting Agents                          
Prescribing Recommendations 
Antacids containing aluminum, calcium, or 
magnesium and iron-containing preparations can 
impair absorption 
Avoid doxycycline administration for 2 
hours before and after any of these 
medications. 
Barbiturates, carbamazepine, and phenytoin 
increase the half-life of doxycycline 
No dose modifications recommended. 
                                               
8.1.6 Adverse Events: 
Gastrointestinal side-effects 
Anorexia, nausea, vomiting, diarrhea, glossitis can occur. Rare instances of 
esophagitis and esophageal ulcerations have been reported in patients receiving 
capsule and table forms of the drug. Most of these patients took the medications 
immediately before going to bed. 
 
Cutaneous reactions 
Photosensitivity manifested by an exaggerated sunburn reaction has been 
observed. Patients should be advised against direct sunlight exposure and to use 
adequate sun protection with sunscreen. Uncommon skin reactions include toxic 
epidermal necrolysis, Stevens-Johnson syndrome, erythema multiforme, 
maculopapular and erythematous rashes and exfoliative dermatitis. 
Renal toxicity 
An increase in blood urea nitrogen from an anti-anabolic action has been reported 
from doxycycline. 
Immune 
Hypersensitivity reactions including urticarial, angioneurotic edema, anaphylaxis, 
anaphylactoid purpura, serum sickness, pericarditis, exacerbation of systemic 
lupus erythematosus and drug rash with eosinophilia and systemic symptoms 
(DRESS) syndrome have been rarely reported. 
 
 

Version Date 08-19-16 
23 
 
Hematologic 
Hemolytic anemia, thrombocytopenia, neutropenia and eosinophilia have been 
reported. 
Dental 
The use of tetracyclines during tooth development (last half of pregnancy, infancy 
and childhood to the age of 8 years) may cause permanent discoloration of teeth 
(yellow-gray-brown). Enamel hypoplasia has also been reported.  
Clostridium difficile associated diarrhea (CDAD) 
CDAD has been reported with the use of nearly all antibacterial agents, including 
doxycycline, and may range in severity from mild diarrhea to fatal colitis.  
8.2 How supplied and Storage/Handling  
Doxycycline monohydrate is available in salmon colored film-coated tablets containing 
doxycycline monohydrate equivalent to 100 mg of doxycycline, bottles of 50 (NDC 
0069-0990-50) 
Doxycycline monohydrate for oral suspension is available as a raspberry-flavored, dry 
powder for oral suspension. When reconstituted, each 5 ml contains doxycycline 
monohydrate equivalent to 25 mg of doxycycline: 2 oz (60 ml) bottles (NDC 0069-0970-
65) 
All products are to be stored below 86ºF (30ºC) and dispensed in tight, light-resistant 
containers (USP). 
8.3 Methods of procurement         
The Froedtert Hospital Departments of Pharmacy will order Doxycycline 100 mg and 
receive drug specifically for this study.  The CTO (at MCW) will be billed for the cost of 
the drug which will be paid for by study funds.  The drug will be dispensed per patient (1 
month supply at a time for systemic amyloidosis; 3 month supply at a time for local 
amyloidosis) and labeled according to more stringent state or federal law.  Drug 
accountability and inventory records will be created and maintained within the 
Investigational Drug Services. 
 
 

Version Date 08-19-16 
24 
 
9. STATISTICAL CONSIDERATIONS 
 
The study is a single-arm phase II trial evaluating the safety and efficacy of doxycycline used in 
adjunct to anti-amyloid treatment to improve organ response in patients with AL amyloidosis. 
The primary objective of this study is to evaluate the cumulative organ response at 1 year. The 
incidence of organ response to conventional chemotherapy at 1 year is approximately 20-25%. 
At the time of publication the results of the study will be retrospectively compared against AL 
amyloidosis patients undergoing chemotherapy alone at our institution in the last 5 years. 
 
For this phase II study, we will use an exact single-stage phase II design. We will consider the 
“experimental” regimen of doxycycline with conventional anti-amyloid treatment to be no more 
effective than conventional anti-amyloid treatment alone, the true probability of organ response 
at 1 year is no less than 25% (p0). We will assume that the new experimental regimen is worthy 
of further study of the true probability of organ response greater than 50% (p1). In statistical 
terms, we are testing the null hypothesis H0: p≤0.25, versus the alternate H1: p≥0.5, where p is 
probability of organ response. Our power analysis indicated that we will need 26 patients to have 
80% power to detect the designed difference at 5% significance level. We will increase the 
sample size by 15% to 30 in order to account for patients with advanced disease who may die 
prior to response. Patients dying prior to response are a competing risk event. The probability of 
response will be calculated using the cumulative incidence curve to accommodate for competing 
risks. Six month and twelve month cumulative incidence rates of response with 95% confidence 
intervals will be reported. Point-wise test will be considered to compare response rates of study 
patients to response rates under standard treatment using historical controls from published 
literature.  
In the final analysis, if 11 or more of the patients develop organ response we will reject the null 
hypothesis. 
We anticipate that a maximum of 30 patients will be accrued to the study. Descriptive statistics 
(i.e. means, standard deviations, 95% confidence intervals for continuous variables, and 
frequencies for discrete data) will be computed for all correlative laboratory parameters. Patients 
who receive <1 month of doxycycline therapy and withdraw from the study will be replaced. 
 
 

Version Date 08-19-16 
25 
 
Safety/Stopping Rules: 
1. 
Development of grade 3-4 adverse events deemed to be related to doxycycline in 6 or 
more patients, will mandate halting further patient accrual until review by DSMB. 
 
Accrual Estimate: 26-30 patients. Patients experiencing mortality within 30 days of starting 
treatment due to disease progression, will be replaced to fully assess 1 year amyloid organ 
response. However, all patients will be included in toxicity and survival analysis. 
 
Accrual Period :  Approximately 12-24 months 
 
 
Follow-Up Period : One year to evaluate incidence of amyloid (hematologic and organ) 
response and relapse pattern. Five years for survival outcomes, relapse, and mortality.  
10. ADVERSE EVENT REPORTING REQUIREMENTS 
10.1  Definitions 
The following are definitions of adverse events as defined by 21CFR312.32. 
 
Types of Adverse Events 
 
Adverse Event means any untoward medical occurrence associated with the use of a 
drug in humans, whether or not consider drug related. 
Life-threatening adverse event or life-threatening suspected adverse reaction:  An 
adverse event or suspected adverse reaction is considered “life-threatening” if, in the 
view of either the investigator or sponsor, its occurrence places the patient or subject at 
immediate risk of death. It does not include an adverse event or suspected adverse 
reaction that, had it occurred in a more severe form, might have caused death. 
 
Serious adverse event or serious suspected adverse reaction:  An adverse event or 
suspected adverse reaction is considered “serious” if, in the view of the investigator or 
sponsor, it results in any of the following outcomes: 
• Death, 
• A life-threatening prolongation of existing hospitalization, 
• A persistent or significant incapacity or substantial disruption of the ability to 
conduct normal life functions, or 
• A congenital anomaly/birth defect. 

Version Date 08-19-16 
26 
 
• Important medical events that may not result in death, be life-threatening, or 
require hospitalization may be considered serious when, based upon appropriate 
medical judgment, they may jeopardize the patient or subject and may require 
medical or surgical intervention to prevent of the outcomes listed above.   
Suspected adverse reaction means any adverse event for which there is a reasonable 
possibility that the drug caused the adverse event.  “Reasonable possibility” means there 
is evidence to suggest a causal relationship between the drug and the adverse event.  
Suspected adverse reaction implies a lesser degree of certainty about causality than 
adverse reaction, which means any adverse event caused by a drug. 
 
Unexpected adverse event or unexpected suspected adverse reaction:  An adverse 
event or suspected adverse reaction is considered “unexpected” if it is not listed in the 
investigator brochure or is not listed at the specificity or severity that has been observed; 
or, if an investigator brochure is not required or available, it is not consistent with the risk 
information currently described.   
Unexpected also refers to adverse events or suspected adverse reactions that are 
mentioned in the investigator brochure as occurring with a class of drugs or as anticipated 
from the pharmacological properties of the drug, but are not specifically mentioned as 
occurring with the particular drug under investigation. 
 
 
Adverse Event Grading 
 
Grade 
Description 
 
0 
No AE (or within normal limits). 
 
1 
Mild; asymptomatic or mild symptoms; clinical or diagnostic 
observations only; intervention not indicated. 
 
2 
Moderate; minimal, local or noninvasive intervention (e.g., packing 
cautery) indicated; limiting age-appropriate instrumental activities of 
daily living (ADL). 
 

Version Date 08-19-16 
27 
 
3 
Severe or medically significant but not immediately life-threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; 
limiting self-care ADL. 
 
4 
Life-threatening consequences; urgent intervention indicated. 
 
5 
Death related to AE 
 
 
Adverse Event Attribution 
 
Relationship 
Attribution 
Description 
Unrelated to 
investigational 
agent/intervention 
Unrelated 
The AE is clearly NOT related to 
the intervention 
Unlikely 
The AE is doubtfully related to 
the intervention 
Related to investigational 
agent/intervention 
Possible 
The AE may be related to the 
intervention 
Probable 
The AE is likely related to the 
intervention 
Definite 
The AE is clearly related to the 
intervention 
 
 
Reporting of Adverse Events 
Because all of the study transplant recipients will be receiving potentially toxic preparative 
therapy, significant regimen related toxicity is expected.  A study specific toxicity CRF 
will be designed to capture information regarding these expected events.  Unexpected 
adverse events will be reported throughout the study. 
 
Unexpected Adverse Events 
Unexpected Grades 3-5 (severe, life threatening, disabling, or fatal) require expedited 
reporting and will be submitted to the DSMC within 5 calendar days of discovery for 
review.  If the Grade 3-5 event is determined to be an unanticipated problem, the event will 
be forwarded to the MCW/FH IRB for review as required by their policy.  Unexpected 
adverse events, regardless of severity, will be reported to the DSMC and reviewed on a 
quarterly basis. 
 
 

Version Date 08-19-16 
28 
 
 
Expected Adverse Events 
Grade 4 (non hematologic) and Grade 5 (fatal) expected adverse events require expedited 
reporting and will be reported to the DSMC within 5 calendar days for review.  Expected 
Grade 4 hematologic and GI toxicity adverse events do not require expedited reporting. 
Expected adverse events that are being captured on the study toxicity form will be reported 
at the time of the form’s scheduled due date.   
 
All DSMC reports and recommendations will be submitted to the IRB for their review. 
 
Adverse Events Occurring after the End of the Study 
 
Follow-up of AEs 
Any unexpected AEs ongoing at the time of study discontinuation will be followed until 
resolution or stable for at least 2 months.  
 
FDA Reporting Procedures  
 
Commercial Agents:    Commercial agents are those agents not provided under an IND 
but obtained instead from a commercial source.  In some cases an agent obtained 
commercially may be used for indications not included in the package label.  The 
following procedures should be followed to determine if an adverse is reportable to the 
FDA: 
 
Refer to the pharmaceutical section of the protocol to determine if an agent is 
investigational or commercial.   
• 
WHAT TO REPORT:  An unexpected, life-threatening (Grade 4) or unexpected, fatal 
(Grade 5) adverse event with an attribution of possible, probable or definite. 
 
• 
WHEN TO REPORT:  These events should be reported within (7) working days. 
 
• 
WHERE TO REPORT:  These adverse events with commercial agents must be 
reported to the FDA using the MedWatch form.  A copy of the MedWatch form can be 

Version Date 08-19-16 
29 
 
obtained from theFDA’s MedWatch web site at www.fda.gov/medwatch.  You can mail 
the reports to the address below or fax it 1-800-332-0178. 
MedWatch 
 
5600 Fishers Lane 
Rockville, MD 20852-9787 
 
11. PATIENT CONSENT AND PEER REVIEW STATEMENT 
11.1 Subject Information and Informed Consent 
 
Written informed consent must be obtained from the subject prior to study participation. 
 
The informed consent document must be signed and dated by the subject and properly 
witnessed (if applicable) before initiation of any study procedures including any change in 
medication or initiation of study drug dosing.   
 
Subjects must be consented in accordance with all local regulatory and legal requirements.  
This process must include a verbal explanation of the nature, scope, and possible 
consequences of the study provided in plain language.  The information should be 
presented by the investigator unless a designee is permitted by local regulations.  The 
potential study subject should be encouraged to ask questions about the study.   
 
The informed consent document must be prepared in accordance with GCP guidelines and 
with local regulatory and legal requirements.  A copy of the signed consent form will be 
given to the subject and the original document must be safely archived by the investigator 
so that the forms can be retrieved at any time for monitoring, auditing, and inspection 
purposes. 
 
The informed consent will be updated as appropriate (e.g., due to protocol amendment or 
if significant new safety information that may be relevant to consent of the subjects 
becomes available).  If the informed consent is revised, it is the investigator’s responsibility 

Version Date 08-19-16 
30 
 
to ensure that an amended consent form is reviewed and signed by all subjects subsequently 
entered into the study and those currently in the study. 
12.  PATIENT REPORTED OUTCOMES ASSESSMENT 
We will collect patient-reported health quality of life in this study.   
 
At baseline, at each subsequent study visit and End of Treatment visit, the study coordinator will 
ask patients to complete a questionnaire to report on common domains of health-related quality 
of life using the Patient Reported Outcomes Measurement Informations System (PROMIS) 
Global Health instrument (See Appendix B), a 10-item standardized patient-reported outcome 
measure that provides global ratings of physical function, fatigue, pain, emotional distress, social 
health, as well as perceptions of general health that cut across these key domains.38 
We will describe the patient experience over the course of the year.  
13. CORRELATIVE SPECIMENS 
We will collect serum from patients at baseline, months 6 and 12. These specimens will be stored 
in the Tissue Bank at MCW. We will perform serum inflammatory markers known to be 
associated with doxycycline use8 to identify possible biomarkers of amyloid response to 
doxycycline. We will obtain MMP-2, MMP-7, MMP-8, MMP-9 and TIMP-1 (tissue inhibitor of 
metalloproteinase-1) levels in all patients at baseline, months 6 and 12 of doxycycline use. To 
measure MMP activity, zymograms will be performed on sera from all the patients.  Briefly, 
zymography is a simple sensitive and functional assay to analyze MMP activity.  Proteins are 
separated by electrophoresis utilizing SDS-PAGE gels containing the according MMP substrate, 
MMP2 and 9 are gelatinases therefore the gel will contain gelatin.  The gel for MMP7 will 
contain casein and for MMP8 collagen-I.  The MMP activity will be measured by the 
degradation of the substrate and therefore the inability of Coomassie Blue to stain the gel at the 
molecular weight appropriate spot.  The TIMP-1 expression will be measured by ELISA utilizing 
TIMP-1 ELISA kit (abcam #ab100651).39,40  Briefly, ELISA is a test that uses antibodies and 
color change to identify an antigen in a liquid substrate measured with a microplate reader. These 
tests will be performed in the Weihrauch Laboratory at MCW using techniques that have already 
been optimized and validated in human sera and myocardial interstitial fluid.41-45 Descriptive 
statistics will be computed for all the correlative laboratory parameters. If a significant difference 

Version Date 08-19-16 
31 
 
is seen in these biomarkers at 6 and 12 months, and organ response is seen (i.e. positive study), 
these results will be used to for further hypothesis generating questions, and phase III design.  
 
14.  REFERENCES 
 
1. 
Sipe JD, Benson MD, Buxbaum JN, et al: Amyloid fibril protein nomenclature: 
2010 recommendations from the nomenclature committee of the International Society of 
Amyloidosis. Amyloid 17:101-4, 2010 
 
2. 
Kumar SK, Gertz MA, Lacy MQ, et al: Recent improvements in survival in 
primary systemic amyloidosis and the importance of an early mortality risk score. Mayo Clin 
Proc 86:12-8, 2011 
 
3. 
Duggar BM: Aureomycin; a product of the continuing search for new antibiotics. 
Ann N Y Acad Sci 51:177-81, 1948 
 
4. 
Nagase H, Woessner JF, Jr.: Matrix metalloproteinases. J Biol Chem 274:21491-
4, 1999 
 
5. 
Keeling J, Herrera GA: Matrix metalloproteinases and mesangial remodeling in 
light chain-related glomerular damage. Kidney Int 68:1590-603, 2005 
 
6. 
Biolo A, Ramamurthy S, Connors LH, et al: Matrix metalloproteinases and their 
tissue inhibitors in cardiac amyloidosis: relationship to structural, functional myocardial changes 
and to light chain amyloid deposition. Circ Heart Fail 1:249-57, 2008 
 
7. 
Golub LM, Lee HM, Ryan ME, et al: Tetracyclines inhibit connective tissue 
breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res 12:12-26, 1998 
 
8. 
Kormi I, Alfakry H, Tervahartiala T, et al: The effect of prolonged systemic 
doxycycline therapy on serum tissue degrading proteinases in coronary bypass patients: a 
randomized, double-masked, placebo-controlled clinical trial. Inflamm Res, 2013 
 
9. 
Greenwald RA, Moak SA, Ramamurthy NS, et al: Tetracyclines suppress matrix 
metalloproteinase activity in adjuvant arthritis and in combination with flurbiprofen, ameliorate 
bone damage. J Rheumatol 19:927-38, 1992 
 
10. 
Griffin MO, Fricovsky E, Ceballos G, et al: Tetracyclines: a pleitropic family of 
compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell 
Physiol 299:C539-48, 2010 
 
11. 
Forloni G, Colombo L, Girola L, et al: Anti-amyloidogenic activity of 
tetracyclines: studies in vitro. FEBS Lett 487:404-7, 2001 
 
12. 
Cardoso I, Merlini G, Saraiva MJ: 4'-iodo-4'-deoxydoxorubicin and tetracyclines 
disrupt transthyretin amyloid fibrils in vitro producing noncytotoxic species: screening for TTR 
fibril disrupters. FASEB J 17:803-9, 2003 
 
13. 
Cardoso I, Martins D, Ribeiro T, et al: Synergy of combined 
doxycycline/TUDCA treatment in lowering Transthyretin deposition and associated biomarkers: 
studies in FAP mouse models. J Transl Med 8:74, 2010 
 
14. 
Cardoso I, Saraiva MJ: Doxycycline disrupts transthyretin amyloid: evidence 
from studies in a FAP transgenic mice model. FASEB J 20:234-9, 2006 
 
15. 
Giorgetti S, Raimondi S, Pagano K, et al: Effect of tetracyclines on the dynamics 
of formation and destructuration of beta2-microglobulin amyloid fibrils. J Biol Chem 286:2121-
31, 2011 

Version Date 08-19-16 
32 
 
 
16. 
Ward JE, Ren R, Toraldo G, et al: Doxycycline reduces fibril formation in a 
transgenic mouse model of AL amyloidosis. Blood 118:6610-7, 2011 
 
17. 
Innes H, Lim SL, Hall A, et al: Management of febrile neutropenia in solid 
tumours and lymphomas using the Multinational Association for Supportive Care in Cancer 
(MASCC) risk index: feasibility and safety in routine clinical practice. Support Care Cancer 
16:485-91, 2008 
 
18. 
Chang WY, Cane JL, Kumaran M, et al: A two year randomised placebo 
controlled trial of doxycycline for lymphangioleiomyomatosis. Eur Respir J, 2013 
 
19. 
Baxter BT, Pearce WH, Waltke EA, et al: Prolonged administration of 
doxycycline in patients with small asymptomatic abdominal aortic aneurysms: report of a 
prospective (Phase II) multicenter study. J Vasc Surg 36:1-12, 2002 
 
20. 
Kumar SK, Dispenzieri A, Lacy MQ, et al: Doxycycline Used As Post Transplant 
Antibacterial Prophylaxis Improves Survival in Patients with Light Chain Amyloidosis 
Undergoing Autologous Stem Cell Transplantation. ASH Annual Meeting Abstracts 120:3138-, 
2012 
 
21. 
Montagna G, Cazzulani B, Obici L, et al: Benefit of doxycycline treatment on 
articular disability caused by dialysis related amyloidosis. Amyloid 20:173-8, 2013 
 
22. 
Palladini G, Perfetti V, Obici L, et al: Association of melphalan and high-dose 
dexamethasone is effective and well tolerated in patients with AL (primary) amyloidosis who are 
ineligible for stem cell transplantation. Blood 103:2936-8, 2004 
 
23. 
Palladini G, Perfetti V, Perlini S, et al: The combination of thalidomide and 
intermediate-dose dexamethasone is an effective but toxic treatment for patients with primary 
amyloidosis (AL). Blood 105:2949-51, 2005 
 
24. 
Dispenzieri A, Lacy MQ, Rajkumar SV, et al: Poor tolerance to high doses of 
thalidomide in patients with primary systemic amyloidosis. Amyloid 10:257-61, 2003 
 
25. 
Finsterer J, Hoftberger R, Stollberger C, et al: Sudden death possibly related to 
lenalidomide given for cardiac and muscle AL amyloidosis secondary to light chain deposition 
disease. J Oncol Pharm Pract 19:170-4, 2013 
 
26. 
Dinner S, Witteles W, Afghahi A, et al: Lenalidomide, melphalan and 
dexamethasone in a population of patients with immunoglobulin light chain amyloidosis with 
high rates of advanced cardiac involvement. Haematologica 98:1593-9, 2013 
 
27. 
Palladini G, Russo P, Foli A, et al: Salvage therapy with lenalidomide and 
dexamethasone in patients with advanced AL amyloidosis refractory to melphalan, bortezomib, 
and thalidomide. Ann Hematol 91:89-92, 2012 
 
28. 
Kumar SK, Hayman SR, Buadi FK, et al: Lenalidomide, cyclophosphamide, and 
dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood 
119:4860-7, 2012 
 
29. 
Dispenzieri A, Buadi F, Laumann K, et al: Activity of pomalidomide in patients 
with immunoglobulin light-chain amyloidosis. Blood 119:5397-404, 2012 
 
30. 
Yamasaki S, Muta T, Higo T, et al: Ventricular fibrillation after bortezomib 
therapy in a patient with systemic amyloidosis. Hematol Rep 5:e12, 2013 
 
31. 
Dimopoulos MA, Kastritis E: Bortezomib for AL amyloidosis: moving forward. 
Blood 118:827-8, 2011 
 
32. 
Dispenzieri A, Gertz MA, Buadi F: What do I need to know about 
immunoglobulin light chain (AL) amyloidosis? Blood Rev 26:137-54, 2012 

Version Date 08-19-16 
33 
 
 
33. 
Kumar SK, Rajkumar SV, Dispenzieri A, et al: Improved survival in multiple 
myeloma and the impact of novel therapies. Blood 111:2516-20, 2008 
 
34. 
Venner CP, Lane T, Foard D, et al: Cyclophosphamide, bortezomib, and 
dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and 
prolonged progression-free survival. Blood 119:4387-90, 2012 
 
35. 
Jaccard A, Moreau P, Leblond V, et al: High-dose melphalan versus melphalan 
plus dexamethasone for AL amyloidosis. N Engl J Med 357:1083-93, 2007 
 
36. 
Eisenhauer EA, Therasse P, Bogaerts J, et al: New response evaluation criteria in 
solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228-47, 2009 
 
37. 
Palladini G, Dispenzieri A, Gertz MA, et al: New criteria for response to 
treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and 
cardiac biomarkers: impact on survival outcomes. J Clin Oncol 30:4541-9, 2012 
 
38. 
Hays RD, Bjorner JB, Revicki DA, et al: Development of physical and mental 
health summary scores from the patient-reported outcomes measurement information system 
(PROMIS) global items. Qual Life Res 18:873-80, 2009 
 
39. 
Xu H, Krolikowski JG, Jones DW, et al: 4F decreases IRF5 expression and 
activation in hearts of tight skin mice. PLoS One 7:e52046, 2012 
 
40. 
Xu H, Zaidi M, Struve J, et al: Abnormal fibrillin-1 expression and chronic 
oxidative stress mediate endothelial mesenchymal transition in a murine model of systemic 
sclerosis. Am J Physiol Cell Physiol 300:C550-6, 2011 
 
41. 
Weihrauch D, Lohr NL, Mraovic B, et al: Chronic hyperglycemia attenuates 
coronary collateral development and impairs proliferative properties of myocardial interstitial 
fluid by production of angiostatin. Circulation 109:2343-8, 2004 
 
42. 
Snoek-van Beurden PA, Von den Hoff JW: Zymographic techniques for the 
analysis of matrix metalloproteinases and their inhibitors. Biotechniques 38:73-83, 2005 
 
43. 
Matsunaga T, Weihrauch DW, Moniz MC, et al: Angiostatin inhibits coronary 
angiogenesis during impaired production of nitric oxide. Circulation 105:2185-91, 2002 
 
44. 
Ludwig LM, Tanaka K, Eells JT, et al: Preconditioning by isoflurane is mediated 
by reactive oxygen species generated from mitochondrial electron transport chain complex III. 
Anesth Analg 99:1308-15; table of contents, 2004 
 
45. 
Gogly B, Groult N, Hornebeck W, et al: Collagen zymography as a sensitive and 
specific technique for the determination of subpicogram levels of interstitial collagenase. Anal 
Biochem 255:211-6, 1998 
 
 
 

Version Date 08-19-16 
34 
 
15. APPENDIX A 
 
Hematologic response definition 
 
 
 
 

Version Date 08-19-16 
35 
 
Organ response criteria 
 
 
 

Version Date 08-19-16 
36 
 
16. APPENDIX B 
 
 

Version Date 08-19-16 
37 
 
 
 

Version Date 08-19-16 
38 
 
 
 

Version Date 08-19-16 
39 
 
 
 

Version Date 08-19-16 
40